Bernstein analyst Rebecca Liang maintained a Hold rating on BeiGene (ONC – Research Report) today and set a price target of $259.00. The ...
Bernstein raised the firm’s price target on BeiGene (ONC) to $259 from $207 and keeps a Market Perform rating on the shares. The firm sees more ...
Beijing-based pharma, BeiGene’s Brukinsa (zanubrutinib) has been approved by the US Food and Drug Administration (FDA) for chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL).
After hours: March 7 at 7:54:21 PM EST Loading Chart for ONC ...
The East New Britain Provincial Assembly held a special sitting today, Friday, March 14, 2025, at the Degenhardt Conference Centre in Vunapope to pay their last respects and to honor one of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results